Acadian Asset Management LLC Purchases Shares of 50,156 Bruker Corporation $BRKR

Key Points

• Acadian Asset Management LLC acquired 50,156 shares of Bruker Corporation, totaling approximately $2,093,000, during Q1.
• Analysts have mixed ratings for Bruker, with target price adjustments ranging from $38.00 to $61.00, and an average rating of "Hold".
• Bruker plans to pay a quarterly dividend of $0.05 per share on October 3rd, reflecting a 0.6% dividend yield.

Acadian Asset Management LLC bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 50,156 shares of the medical research company's stock, valued at approximately $2,093,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Captrust Financial Advisors raised its stake in shares of Bruker by 32.7% in the fourth quarter. Captrust Financial Advisors now owns 5,973 shares of the medical research company's stock valued at $350,000 after purchasing an additional 1,472 shares in the last quarter. Cetera Investment Advisers boosted its holdings in Bruker by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 23,083 shares of the medical research company's stock valued at $1,353,000 after acquiring an additional 2,799 shares during the last quarter. Nomura Holdings Inc. boosted its holdings in Bruker by 109.8% in the fourth quarter. Nomura Holdings Inc. now owns 14,684 shares of the medical research company's stock valued at $861,000 after acquiring an additional 7,684 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Bruker by 210.3% in the fourth quarter. Quantinno Capital Management LP now owns 12,057 shares of the medical research company's stock valued at $707,000 after buying an additional 8,172 shares during the period. Finally, ProShare Advisors LLC lifted its stake in Bruker by 19.9% in the fourth quarter. ProShare Advisors LLC now owns 9,813 shares of the medical research company's stock valued at $575,000 after buying an additional 1,626 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of research analyst reports. Stifel Nicolaus set a $40.00 price target on Bruker and gave the stock a "hold" rating in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Citigroup dropped their price target on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Barclays dropped their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Finally, Bank of America lowered their price target on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $51.30.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares of the company's stock, valued at approximately $581,016. The trade was a 16.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 27.30% of the stock is owned by company insiders.

Bruker Stock Down 0.3%

Shares of BRKR stock traded down $0.10 during trading hours on Friday, hitting $33.17. 4,515,094 shares of the company's stock traded hands, compared to its average volume of 4,663,026. The stock's fifty day simple moving average is $35.03 and its two-hundred day simple moving average is $38.46. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $72.94. The stock has a market cap of $5.03 billion, a price-to-earnings ratio of 63.79, a PEG ratio of 4.62 and a beta of 1.21. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. During the same quarter in the previous year, the business posted $0.52 earnings per share. Bruker's revenue for the quarter was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker's dividend payout ratio is 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.